HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 25, No. 06, June 2021 – Hope for Inoperable Kidney Cancer       » Artificial Muscle Inspired by Muscle Fibre       » Improving Crop Production with Novel Matrix-Based Slow-Release Urea       » Strategic Partnership Forged to Advance Healthcare Delivery in Southeast Asia       » Phillips Releases Future Health Index 2021 Report       » A Wake-up Call from the Seabed      
Vol 24, No. 09, September 2020   |   Issue PDF view/purchase
INSIDE INDUSTRY
Results of CD30 CAR-T Cell Therapy Trial Shows Promise for Hodgkin Lymphoma Patients
Clinical-stage cell therapy company, Tessa Therapeutics announced the results of two independent Phase 1/2 trials of autologous CD30 CAR-T cell therapy in patients with relapsed or refractory Hodgkin Lymphoma.

Hodgkin Lymphoma is a type of cancer which stems from white blood cells known as lymphocytes. It is one of two types of cancers originating from the lymphatic system. In a recent publication released in the Journal of Clinical Oncology two investigator-sponsored Phase 1/2 trials evaluating the safety and efficacy of CD30 CAR-T cell therapy on patients with relapsed or refractory Hodgkin Lymphoma were released.

The trials were led by Baylor College of Medicine and the University of North Carolina Lineberger Comprehensive Cancer Centre. In the trial, autologous CD30 CAR-T cell therapy was tested which meant the use of the patient’s own cells for the therapy. Results of the trials demonstrated a positive responses and very favourable safety profile.

41 adult patients were enrolled for the trials with relapsed or refractory Hodgkin Lymphoma to receive the autologous CD30 CAR-T cell therapy after lymphodepletion with chemotherapy. Out of all the treated patients, 94 percent survival a year after treatment. 61 percent of the patients who showed complete responses had no evidence of recurrence one year later.

No serious or life-threatening complications were observed among the patients as compared to those seen in several CD19 CAR-T cell trials. Overall, the response rate in the 32 patients with active disease who received fludarabine-based lymphodepletion was 72 percent, including 19 patients (59%) with complete response.

“These data are significant, as they demonstrate that CAR-T cell therapy may be a safe and

effective treatment option for patients with Hodgkin lymphoma and potentially other lymphomas expressing the CD30 antigen,” said Dr. Natalie Grover, study co-first author, assistant professor in the UNC Department of Medicine and a UNC Lineberger member.

The university of North Carolina and Baylor College of Medicine have both granted Tessa an exclusive license to its patents, data and knowhow, for the further development and commercialization of this therapy.

“We have been working with Baylor and the University of North Carolina to confirm these

impressive results further in a Tessa-sponsored regulatory Phase 2 trial, which we aim to initiate this year,” said Ivan D. Horak, M.D., President of Research and Development at Tessa Therapeutics.

“Longer term, we seek to explore the potential of this therapy beyond Hodgkin’s lymphoma to CD30+ expressing Non-Hodgkin lymphomas, where there is a demonstrated unmet need.”

“We are excited to collaborate with Tessa. Their ability to run multi-center cell therapy clinical trials will be invaluable for the further development of this therapy,” said Helen Heslop, director of the Center for Cell and Gene Therapy and Dan L Duncan Chair at Baylor.

 

FORTHCOMING ISSUE  
Oliver Healthcare Packaging Wins “Packaging Design of the Year” at Healthcare Asia Medtech Awards 2021
NEWS CRUNCH  
news Anti-Pandemic Forum to be Hosted by Top-Notch American and Chinese Scientists
news Commemorating World Health Day with Viatris
news Entire industrial chain resources of advanced medical equipment are lining up at Medtec China 2021
news CPhI & P-MEC China gives a glimpse of the success returning pharma events will deliver in 2021
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy